New drug combo tested to help frail AML patients live longer

NCT ID NCT02752035

Summary

This study tested whether adding a new drug called gilteritinib to standard azacitidine treatment helps adults with a specific type of acute myeloid leukemia (AML) live longer. It focused on older adults or those with other health problems who could not tolerate strong chemotherapy. Researchers randomly assigned participants to receive either the two-drug combination or azacitidine alone to compare survival and other outcomes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GHS Cancer Institute

    Greenville, South Carolina, 26615, United States

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • Hematology-Oncology Associates of Northern NJ

    Morristown, New Jersey, 07962, United States

  • LDS Hospital

    Salt Lake City, Utah, 84143, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10021, United States

  • Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois, 60611-5975, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • Site AU61004

    Liverpool, New South Wales, 2170, Australia

  • Site AU61007

    Geelong, Victoria, 3220, Australia

  • Site AU61008

    Adelaide, South Australia, SA 5000, Australia

  • Site BE32003

    Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

  • Site BE32006

    Ghent, 9000, Belgium

  • Site BE32007

    Brussels, Brussels Capital, 1090, Belgium

  • Site CA15002

    Toronto, Ontario, M5G 2M9, Canada

  • Site CA15006

    Montreal, Quebec, H4A 3J1, Canada

  • Site CA15009

    Edmonton, Alberta, T6G 2B7, Canada

  • Site CA15011

    Toronto, Ontario, M4N 3M5, Canada

  • Site DE49002

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Site DE49003

    Berlin, 13353, Germany

  • Site DE49004

    Hanover, Lower Saxony, 30625, Germany

  • Site DE49005

    Frankfurt am Main, Hesse, 60590, Germany

  • Site DE49007

    München, Bavaria, 81737, Germany

  • Site DE49009

    Halle, Saxony-Anhalt, 06120, Germany

  • Site DE49011

    Stuttgart, 70376, Germany

  • Site DE49012

    Braunschweig, Lower Saxony, 38118, Germany

  • Site DE49015

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • Site ES34002

    Cáceres, 10003, Spain

  • Site ES34003

    Oviedo, Principality of Asturias, 33011, Spain

  • Site ES34004

    Barcelona, 08035, Spain

  • Site ES34005

    Valencia, 46026, Spain

  • Site ES34007

    Palma de Mallorca, Balearic Islands, 07010, Spain

  • Site ES34008

    Barcelona, 08003, Spain

  • Site ES34009

    Barcelona, 8041, Spain

  • Site ES34010

    Barcelona, 08036, Spain

  • Site ES34013

    Madrid, Spain

  • Site FR33001

    Nantes, Loire-Atlantique, 44093, France

  • Site FR33002

    Pessac, Gironde, 33604, France

  • Site FR33003

    Nîmes, Gard, 30029, France

  • Site FR33004

    Lille, 59020, France

  • Site FR33006

    Lille, 59037, France

  • Site FR33009

    Angers, 49033, France

  • Site FR33012

    Poitiers, Vienne, 86000, France

  • Site FR33013

    Pierre-Bénite, Rhone, 69310, France

  • Site FR33015

    Rouen, Haute-Normandie, 76038, France

  • Site FR33017

    Le Mans, Sarthe, 72037, France

  • Site FR33018

    Rennes, Ille-et-Vilaine, 35033, France

  • Site FR33019

    Montpellier, Herault, 34295, France

  • Site FR33020

    Bayonne, France

  • Site FR33023

    Valenciennes, Nord, 59322, France

  • Site GB44007

    Sheffield, S10 2JF, United Kingdom

  • Site IT39001

    Naples, 80131, Italy

  • Site IT39004

    Milan, 20162, Italy

  • Site IT39005

    Pavia, Italy

  • Site IT39006

    Palermo, 90146, Italy

  • Site IT39007

    Monza, Italy

  • Site IT39009

    Ancona, 60126, Italy

  • Site IT39011

    San Giovanni Rotondo, 71013, Italy

  • Site IT39012

    Florence, Italy

  • Site IT39014

    Novara, Italy

  • Site IT39015

    Bologna, 40138, Italy

  • Site JP81001

    Isehara, Kanagawa, Japan

  • Site JP81004

    Nagasaki, Japan

  • Site JP81005

    Kumamoto, Japan

  • Site JP81007

    Nagoya, Aichi-ken, Japan

  • Site JP81008

    Fukuoka, Japan

  • Site JP81011

    Kurashiki, Okayama-ken, Japan

  • Site JP81012

    Sendai, Miyagi, Japan

  • Site JP81014

    Shinagawa-ku, Tokyo, Japan

  • Site JP81015

    Kobe, Hyōgo, Japan

  • Site JP81016

    Kyoto, Japan

  • Site JP81017

    Nagasaki, Japan

  • Site JP81018

    Anjo, Aichi-ken, Japan

  • Site JP81019

    Toyama, Japan

  • Site JP81021

    Fukuyama, Hiroshima, Japan

  • Site JP81023

    Kanazawa, Ishikawa-ken, Japan

  • Site JP81024

    Gifu, Japan

  • Site JP81026

    Tokushima, Japan

  • Site JP81027

    Matsuyama, Ehime, Japan

  • Site JP81029

    Shibuya-ku, Tokyo, Japan

  • Site JP81030

    Osaka, Japan

  • Site JP81031

    Sapporo, Hokkaido, Japan

  • Site JP81032

    Yokohama, Kanagawa, Japan

  • Site JP81033

    Sapporo, Hokkaido, Japan

  • Site JP81034

    Hitachi, Ibaraki, Japan

  • Site JP81035

    Chiba, Japan

  • Site JP81036

    Osaka, Japan

  • Site KR82001

    Ulsan, Ulsan Gwang'yeogsi, 682-714, South Korea

  • Site KR82002

    Seoul, Seoul Teugbyeolsi, 137-701, South Korea

  • Site KR82003

    Namdong, Incheon Gwang'yeogsiv, 405 760, South Korea

  • Site KR82006

    Seoul, Seoul Teugbyeolsi, 110-744, South Korea

  • Site KR82010

    Hwasun-gun, South Korea

  • Site KR82012

    Seoul, 156-707, South Korea

  • Site KR82013

    Seoul, Seoul Teugbyeolsi, 05505, South Korea

  • Site KR82014

    Busan, 49241, South Korea

  • Site KR82015

    Seongnam-si, South Korea

  • Site PL48001

    Olsztyn, Warmian-Masurian Voivodeship, 10-228, Poland

  • Site PL48002

    Opole, Opole Voivodeship, 45-061, Poland

  • Site PL48003

    Lublin, Lublin Voivodeship, 20-081, Poland

  • Site PL48004

    Warsaw, Masovian Voivodeship, 02-776, Poland

  • Site TW88601

    Taipei, 10002, Taiwan

  • Site TW88602

    Tainan, 704, Taiwan

  • Site TW88604

    Kaohsiung City, 83301, Taiwan

  • Site TW88605

    Kwei Shan Hsiang, Taiwan

  • Site TW88608

    Taipei, 10449, Taiwan

  • Site TW88609

    Tainan, 736, Taiwan

  • Site TW88610

    Taipei, 11217, Taiwan

  • St. Louis University Cancer Center - Hematology/Oncology

    St Louis, Missouri, 63110, United States

  • UCLA David Geffen School of Medicine

    Los Angeles, California, 90095, United States

  • University of California, Irvine Medical Center

    Orange, California, 92868, United States

  • Weill Cornell Medical College-New York Presbyterian Hospital

    New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.